Targeted Alpha-Particle Therapy: A Review of Current Trials.
Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O.
Int J Mol Sci. 2023 Jul 19;24(14):11626. doi: 10.3390/ijms241411626.
Alpha-particle microdosimetry.
Chouin N, Bardies M.
Curr Radiopharm. 2011 Jul;4(3):266-80. doi: 10.2174/1874471011104030266.
Alpha emitting nuclides for targeted therapy.
Hatcher-Lamarre JL, Sanders VA, Rahman M, Cutler CS, Francesconi LC.
Nucl Med Biol. 2021 Jan;92:228-240. doi: 10.1016/j.nucmedbio.2020.08.004. Epub 2020 Sep 1.
Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future.
Rabiei M, Asadi M, Yousefnia H.
Curr Radiopharm. 2024;17(1):7-13. doi: 10.2174/0118744710262325231025075638.
Targeted alpha-Emitter Therapy of Neuroendocrine Tumors.
Kunikowska J, Królicki L.
Semin Nucl Med. 2020 Mar;50(2):171-176. doi: 10.1053/j.semnuclmed.2019.11.003.
The Case for Dosimetry in Alpha-Emitter Therapy.
Sgouros G.
J Med Imaging Radiat Sci. 2019 Dec;50(4 Suppl 1):S45-S46. doi: 10.1016/j.jmir.2019.07.007. Epub 2019 Sep 16.
225Ac-PSMA-617 for Therapy of Prostate Cancer.
Kratochwil C, Haberkorn U, Giesel FL.
Semin Nucl Med. 2020 Mar;50(2):133-140. doi: 10.1053/j.semnuclmed.2020.02.004. Epub 2020 Feb 14.
Targeted Alpha-Particle Therapy for Hematologic Malignancies.
Jurcic JG.
Semin Nucl Med. 2020 Mar;50(2):152-161. doi: 10.1053/j.semnuclmed.2019.09.002. Epub 2019 Nov 25.
Challenges and opportunities in developing Actinium-225 radiopharmaceuticals.
Dhiman D, Vatsa R, Sood A.
Nucl Med Commun. 2022 Sep 1;43(9):970-977. doi: 10.1097/MNM.0000000000001594. Epub 2022 Jun 23.
Targeted Radioimmunotherapy and Theranostics with Alpha Emitters.
Pandit-Taskar N.
J Med Imaging Radiat Sci. 2019 Dec;50(4 Suppl 1):S41-S44. doi: 10.1016/j.jmir.2019.07.006. Epub 2019 Aug 23.
